TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7790289

Group type: EXPERIMENTAL
Intervention: Program H (high intensity and variety of stimuli)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Program HL (transient from high to low)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Program L (low stimulation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All programs
Number of subjects: 20
Study: 2185977

Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3% sodium tetradecyl sulfate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Absolute alcohol
Number of subjects: 90
Study: 467482

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN), 5 mg, sublingually
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nifedipine (N), 10 mg, orally
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Verapamil (V), 160 mg, orally
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Propranolol (Pr), 40 mg, orally
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 5
Study: 31268224

Group type: EXPERIMENTAL
Intervention: Guided Self‐Determination‐Young (GSD‐Y) intervention, 7 group training sessions over 5 months
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Guided Self‐Determination‐Young (GSD‐Y) intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 71
Study: 26675352

Group type: EXPERIMENTAL
Intervention: Bone Power program (theory-based online bone health program)
Number of subjects: 866

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 866
Study: 25843674

Group type: EXPERIMENTAL
Intervention: Lotrafilcon B (Air Optix(®)AQUA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balafilcon A (PureVision™)
Number of subjects: 60
Study: 23497630

Group type: EXPERIMENTAL
Intervention: Telephone counseling delivered by VA staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone counseling delivered by state quitlines
Number of subjects: 0
Study: 21871667

Group type: EXPERIMENTAL
Intervention: Solution-Focused Therapy (SFT)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Short-Term Psychodynamic Psychotherapy (SPP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Long-Term Psychodynamic Psychotherapy (LPP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Psychoanalysis (PA)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Short-Term Therapy
Number of subjects: 326
Study: 19356391

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200 mg once daily for 6 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metformin hydrochloride 850 mg single-dose
Number of subjects: 20
Study: 18193500

Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid (PLA) injections administered every 2 weeks for 4 treatments
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (deferred PLA treatment)
Number of subjects: 101
Study: 15043527

Group type: EXPERIMENTAL
Intervention: Digital 50 degrees red‐free imaging
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Two-field 50 degrees colour imaging
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Two-field 45 degrees colour imaging
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hand-held digital colour videocamera (MediTell)
Number of subjects: 70
Study: 11136493

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 1009
Study: 9747746

Group type: EXPERIMENTAL
Intervention: Intravenous IL-2 (9 Mio I.U. per day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subcutaneous IL-2 (9 Mio I.U. per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (Intravenous and Subcutaneous IL-2)
Number of subjects: 20
Study: 8878381

Group type: EXPERIMENTAL
Intervention: FK506 (low trough level 5-14 ng/ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FK506 (medium trough level 15-25 ng/ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FK506 (high trough level 26-40 ng/ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aggregate of all FK506-treated patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FK506 (all concentrations)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FK506 (increasing maximum trough concentrations)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FK506 (decreasing minimum trough concentrations)
Number of subjects: 120
Study: 2265113

Group type: EXPERIMENTAL
Intervention: hM-CSF (2 x 10(5) units/kg daily from day 1 to day 14 after BMT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 6985681

Group type: EXPERIMENTAL
Intervention: Subsalicylate bismuth
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 31920296

Group type: EXPERIMENTAL
Intervention: BGF MDI 320/18/9.6 μg
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: GFF MDI 18/9.6 μg
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: BUD/FORM DPI 400/12 μg
Number of subjects: 416
Study: 28635557

Group type: EXPERIMENTAL
Intervention: Standard subunit TIV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted subunit TIV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard split-virus TIV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intradermal split-virus TIV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 120
Study: 25668581

Group type: EXPERIMENTAL
Intervention: Erhuangfang (treatment group, n=50)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (n=43)
Number of subjects: 67
Study: 24373547

Group type: EXPERIMENTAL
Intervention: Filtered sunlight phototherapy (FS-PT)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Conventional phototherapy (CPT)
Number of subjects: 616
Study: 20126269

Group type: EXPERIMENTAL
Intervention: Long-lasting insecticidal nets (LN) distributed cluster-wide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 18023995

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 0
Study: 16651569

Group type: EXPERIMENTAL
Intervention: Periarticular intraoperative injection containing ropivacaine, ketorolac, epimorphine, and epinephrine
Number of subjects: 64

Group type: COMPARATOR
Intervention: No injection (Control)
Number of subjects: 64
Study: 14645314

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC)
Number of subjects: 676
Study: 10967001

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pre-treatment (Control)
Number of subjects: 0
Study: 8949810

Group type: EXPERIMENTAL
Intervention: Droperidol added to morphine infusion
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control group (no droperidol)
Number of subjects: 398
Study: 2023758

Group type: EXPERIMENTAL
Intervention: Keeping eyelids closed for 2 minutes after drop placement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Keeping eyelids closed for 2 to 5 minutes after drop placement
Number of subjects: 12
Study: 6784982

Group type: EXPERIMENTAL
Intervention: Long-acting analogue of met-enkephalin (DAMME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (long-term infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose DAMME infusion
Number of subjects: 0
Study: 31419294

Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (7G8) with 8x102 PfSPZ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (7G8) with 4.8x103 PfSPZ
Number of subjects: 0
Study: 28903864

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate and vilanterol (100 μg or 200 μg with 25 μg vilanterol)
Number of subjects: 4233

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate and vilanterol
Number of subjects: 4233

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4233
Study: 25857703

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (four sessions of group trainings and cooking demonstrations over 5 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 20
Study: 23122512

Group type: EXPERIMENTAL
Intervention: Educational program consisting of four educational sessions on epilepsy, including a self-management plan.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no educational program).
Number of subjects: 60
Study: 21724195

Group type: EXPERIMENTAL
Intervention: Sublobar resection with brachytherapy (SRB)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Sublobar resection alone (SR)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Lower-lobe tumors
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Upper-lobe tumors
Number of subjects: 224
Study: 19410392

Group type: EXPERIMENTAL
Intervention: DHEA 50mg daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 93
Study: 17493402

Group type: EXPERIMENTAL
Intervention: Patients with CAN
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients without CAN
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 18
Study: 15068141

Group type: EXPERIMENTAL
Intervention: Tissue Harmonic Imaging (THI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fundamental Imaging (FI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison with MRI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inter-observer variability
Number of subjects: 20
Study: 11803660

Group type: EXPERIMENTAL
Intervention: Bone grafts with hard tissue replacement synthetic bone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated sockets (control)
Number of subjects: 18
Study: 9508013

Group type: EXPERIMENTAL
Intervention: Milk diet (360 mL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Juice diet (540 mL)
Number of subjects: 21
Study: 8001541

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 5 g.day‐1 for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0
Study: 2969930

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single blind placebo
Number of subjects: 16
Study: 29637845

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Circuit only weekly performances
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control
Number of subjects: 145
Study: 28486426

Group type: EXPERIMENTAL
Intervention: Low GI diet (isomaltulose, PalatinoseTM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High GI diet (sucrose)
Number of subjects: 20
Study: 25531413

Group type: EXPERIMENTAL
Intervention: Intrauterine injection of 500 IU hCG before embryo transfer
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo (tissue culture media) before embryo transfer
Number of subjects: 483
Study: 24060300

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg of triamcinolone acetonide (TA) plus grid laser photocoagulation (GLP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Grid laser photocoagulation (GLP)
Number of subjects: 30
Study: 21340561

Group type: EXPERIMENTAL
Intervention: Nasal steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal airway surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18445106

Group type: EXPERIMENTAL
Intervention: Ethanol high concentration (breathalyzer = 0.100 g/dl)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ethanol low concentration (breathalyzer = 0.040 g/dl)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of FHP to FHN subjects
Number of subjects: 60
Study: 16784923

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15058045

Group type: EXPERIMENTAL
Intervention: Group A (progressive workload)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group B (interval training)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Group C (no training)
Number of subjects: 42
Study: 11020003

Group type: EXPERIMENTAL
Intervention: Interferon alpha2b plus ribavirin (1000 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Double dosage of alpha‐interferon (6 million units tiw)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferon alpha2b (3 million units 3 times a week)
Number of subjects: 60
Study: 9093599

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of anti-TNF alpha Fab, 30 min before penicillin in 20 patients
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (n = 29)
Number of subjects: 49
Study: 8179545

Group type: EXPERIMENTAL
Intervention: Routine 2‐stage examination (early dating and 34‐week scan)
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Only a dating scan and additional scans as generated by clinical situations
Number of subjects: 1528
Study: 3153213

Group type: EXPERIMENTAL
Intervention: Regimen A (five different drug associations including VM26 and IDMTX in a sequential schedule)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Regimen B (classical Spiers schedule for the first year, followed by milder treatment)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patients relapsing after 12 months from suspension of treatment in first complete remission
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patients relapsing within the first year off therapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group A (Regimen A)
Number of subjects: 102
Study: 30209050

Group type: EXPERIMENTAL
Intervention: High dose folic acid (4.0 mg/day, four 1.0 mg oral tablets) from 8 weeks of gestation to week 16 until delivery.
Number of subjects: 2464

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 2464
Study: 26495961

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 24494804

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 45

Group type: COMPARATOR
Intervention: Microsurgery
Number of subjects: 45
Study: 22520140

Group type: EXPERIMENTAL
Intervention: Oral pentavalent rotavirus vaccine (PRV), RotaTeq, 3 doses at approximately 6, 10, and 14 weeks of age
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Oral pentavalent rotavirus vaccine (PRV), RotaTeq
Number of subjects: 1960

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1960
Study: 20118150

Group type: EXPERIMENTAL
Intervention: Triple group (cilostazol 100 mg twice daily + clopidogrel 75 mg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High maintenance dose (MD) group (clopidogrel 150 mg daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard group (clopidogrel 75 mg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Triple group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High maintenance dose (MD) group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 90
Study: 18198640

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI), intravenously dripped once daily, starting 3 days before radiotherapy to 1 week after the end of it.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional radiotherapy (Control group).
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI).
Number of subjects: 58
Study: 16305269

Group type: EXPERIMENTAL
Intervention: Clinic treatment group (supervised exercise, individualized manual therapy, home exercise program)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Home exercise group (home exercise program)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Clinic treatment group
Number of subjects: 134
Study: 12218500

Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5% (LP)
Number of subjects: 96
Study: 9468746

Group type: EXPERIMENTAL
Intervention: BT + PSA
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BT
Number of subjects: 108

Group type: COMPARATOR
Intervention: WLE
Number of subjects: 108
Study: 7637923

Group type: EXPERIMENTAL
Intervention: Brisk walking alone
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Salt restriction alone
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Combined intervention (brisk walking + salt restriction)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 181
Study: 2575450

Group type: EXPERIMENTAL
Intervention: trans-Dihydrolisuride (terguride)
Number of subjects: 10
Study: 31562105

Group type: EXPERIMENTAL
Intervention: Soft haptic finger‐worn wearable device using TCP actuators
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vibrotactile feedback system
Number of subjects: 14
Study: 25972128

Group type: EXPERIMENTAL
Intervention: BE‐ACTIV intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Walking and Talking intervention
Number of subjects: 18
Study: 25781654

Group type: COMPARATOR
Intervention: BCAA infusion (N = 5) during insulin infusion at 40 mU/m2/min
Number of subjects: 17

Group type: COMPARATOR
Intervention: BCAA infusion (N = 4) during insulin infusion at 80 mU/m2/min
Number of subjects: 17
Study: 23953658

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 315
Study: 22030938

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG), applied 4 g to 1 or both knees 4 times daily for 9 to 12 months.
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG).
Number of subjects: 583
Study: 18390970

Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) chemotherapy
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: High-dose CAF chemotherapy
Number of subjects: 1572
Study: 16622437

Group type: COMPARATOR
Intervention: General practitioners follow-up
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Surgeons follow-up
Number of subjects: 203
Study: 14569523

Group type: EXPERIMENTAL
Intervention: 75% mandibular advancement (MA)
Number of subjects: 86
Study: 11113048

Group type: EXPERIMENTAL
Intervention: Dialysis-dependent renal failure patients
Number of subjects: 279

Group type: COMPARATOR
Intervention: Other CABG patients (control group)
Number of subjects: 279
Study: 9026840

Group type: EXPERIMENTAL
Intervention: lovastatin (20 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: bezafibrate (400 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 21
Study: 1620456

Group type: EXPERIMENTAL
Intervention: IgIv 0.2 g/kg on day 0, day 2, day 5, day 12
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 6465622

Group type: EXPERIMENTAL
Intervention: Aerosolized terbutaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous epinephrine
Number of subjects: 0
Study: 30789207

Group type: EXPERIMENTAL
Intervention: SCT-based intervention
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 230
Study: 30231894

Group type: EXPERIMENTAL
Intervention: Training via locally made educational videos on low-cost Android tablets
Number of subjects: 129

Group type: COMPARATOR
Intervention: Traditional training through a 1-day in-person workshop
Number of subjects: 129
Study: 26900961

Group type: EXPERIMENTAL
Intervention: Active stimulation (2 mA for 30 minutes)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 120
Study: 24152086

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate (200 μg for 7 days, then 800 μg for 7 days from a dry powder inhaler)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous fluticasone furoate (250 μg infusion)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate (200 μg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate (200 μg and 800 μg)
Number of subjects: 80
Study: 22044753

Group type: EXPERIMENTAL
Intervention: catumaxomab
Number of subjects: 258

Group type: COMPARATOR
Intervention: control
Number of subjects: 258
Study: 20655662

Group type: EXPERIMENTAL
Intervention: Standard treatment+cognitive‐behavioral skills training (STD+CBT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard treatment (STD)
Number of subjects: 101
Study: 16217588

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (RLX60)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day and 150 mg/day (RLX120/150)
Number of subjects: 0
Study: 14663300

Group type: EXPERIMENTAL
Intervention: High intensity intervention group (A) - lifestyle counselling and group-based counselling
Number of subjects: 12816

Group type: COMPARATOR
Intervention: Low intensity intervention group (B) - referred to GP
Number of subjects: 12816

Group type: COMPARATOR
Intervention: Control group (C) - followed by questionnaire
Number of subjects: 12816
Study: 14733645

Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2) plus Gemcitabine (1000 mg/m2) plus Vinorelbine (25 mg/m2) (PGV)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cisplatin (100 mg/m2) plus Gemcitabine (1000 mg/m2) (PG)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cisplatin (120 mg/m2) plus Vinorelbine (30 mg/m2/week) (PV)
Number of subjects: 180
Study: 9196598

Group type: EXPERIMENTAL
Intervention: 1 microgram/kg body weight GHRH bolus at 0 minutes (group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Two consecutive 1 microgram/kg body weight GHRH boluses at 0 and 120 minutes (group II)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Two consecutive 1 microgram/kg body weight hexarelin boluses at 0 and 120 minutes (group II)
Number of subjects: 36